JP2021525236A5 - - Google Patents
Info
- Publication number
- JP2021525236A5 JP2021525236A5 JP2020564482A JP2020564482A JP2021525236A5 JP 2021525236 A5 JP2021525236 A5 JP 2021525236A5 JP 2020564482 A JP2020564482 A JP 2020564482A JP 2020564482 A JP2020564482 A JP 2020564482A JP 2021525236 A5 JP2021525236 A5 JP 2021525236A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862673426P | 2018-05-18 | 2018-05-18 | |
| US62/673,426 | 2018-05-18 | ||
| PCT/IB2019/054104 WO2019220412A2 (en) | 2018-05-18 | 2019-05-17 | Safe and effective method of treating lupus with anti-il12/il23 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525236A JP2021525236A (ja) | 2021-09-24 |
| JP2021525236A5 true JP2021525236A5 (enExample) | 2022-05-25 |
| JP7421500B2 JP7421500B2 (ja) | 2024-01-24 |
Family
ID=68532802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564482A Active JP7421500B2 (ja) | 2018-05-18 | 2019-05-17 | 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11578124B2 (enExample) |
| EP (1) | EP3793521A4 (enExample) |
| JP (1) | JP7421500B2 (enExample) |
| WO (1) | WO2019220412A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| MA54562A (fr) * | 2018-12-18 | 2021-10-27 | Janssen Biotech Inc | Méthode sûre et efficace de traitement du lupus avec un anticorps anti-il12/il23 |
| AU2020386669A1 (en) * | 2019-11-19 | 2022-06-02 | Novartis Ag | Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists |
| CN113035299B (zh) * | 2021-04-02 | 2022-03-29 | 上海药明津石医药科技有限公司 | 分中心推荐方法、装置、计算机设备和存储介质 |
| JP2024536320A (ja) * | 2021-10-04 | 2024-10-04 | アストラゼネカ・アクチエボラーグ | ループスの処置 |
| WO2024100139A1 (en) * | 2022-11-09 | 2024-05-16 | Merck Patent Gmbh | Use of ifn-i activity as a biomarker for tlr inhibitor treatment |
| WO2024102200A1 (en) * | 2022-11-10 | 2024-05-16 | Ampel Biosolutions, Llc | Methods and systems for evaluation of lupus based on ancestry-associated molecular pathways |
| WO2024129960A2 (en) * | 2022-12-16 | 2024-06-20 | Vetmab Biosciences, Inc. | Anti-il23 and anti-tnfα antibodies: compositions and veterinary use |
| WO2025024237A2 (en) * | 2023-07-21 | 2025-01-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of il-12 related biomarkers and il-12 specific blocking antibodies for the treatment of an autoimmune disease |
| WO2025143577A1 (ko) * | 2023-12-28 | 2025-07-03 | 아주대학교 산학협력단 | 전신 홍반성 루푸스 플레어 예측용 바이오마커 |
| US12494266B1 (en) * | 2024-06-10 | 2025-12-09 | Recursion Pharmaceuticals, Inc. | Utilizing a clinical-phenomics causal discovery framework to generate causal discovery predictions |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811523A (en) | 1988-11-10 | 1998-09-22 | Trinchieri; Giorgio | Antibodies to natural killer stimulatory factor |
| ATE140483T1 (de) | 1988-11-10 | 1996-08-15 | Genetics Inst | Natürlicher killerzellen-stimulationsfaktor |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US5780597A (en) | 1989-12-22 | 1998-07-14 | Hoffmann-La Roche Inc. | Monoclonal antibodies to cytotoxic lymphocyte maturation factor |
| DE69034249T2 (de) | 1989-12-22 | 2008-05-29 | F. Hoffmann-La Roche Ag | Monoklonale Antikörper spezifisch für den zytotoxischen Lymphozyten-Reifefaktor |
| WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DE4315127A1 (de) | 1993-05-07 | 1994-11-10 | Behringwerke Ag | Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12 |
| CA2125763C (en) | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| ZA95960B (en) | 1994-03-14 | 1995-10-10 | Genetics Inst | Use of interleukin-12 antagonists in the treatment of autoimmune diseases |
| JP3350551B2 (ja) | 1994-04-22 | 2002-11-25 | コリクサ コーポレイション | 保護的免疫応答及びｉｌ−１２産生の刺激及び促進のための化合物及び方法 |
| US5891680A (en) | 1995-02-08 | 1999-04-06 | Whitehead Institute For Biomedical Research | Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12 |
| US5853697A (en) | 1995-10-25 | 1998-12-29 | The United States Of America, As Represented By The Department Of Health & Human Services | Methods of treating established colitis using antibodies against IL-12 |
| AU6150498A (en) | 1997-02-07 | 1998-08-26 | Wistar Institute, The | Methods and compositions for the inhibition of interleukin-12 production |
| US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
| CN101274962A (zh) | 1998-01-23 | 2008-10-01 | 霍夫曼-拉罗奇有限公司 | 人il-12抗体 |
| DE69927520T2 (de) | 1998-12-09 | 2006-06-22 | Protein Design Labs, Inc., Fremont | Verwendung von il-12 antikörpern zur behandlung von psoriasis |
| HUP0200575A3 (en) | 1999-03-25 | 2004-11-29 | Abbott Gmbh & Co Kg | Human antibodies that bind human il-12 and methods for producing |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| WO2001019373A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| MY157915A (en) | 2004-12-21 | 2016-08-15 | Centocor Inc | Anti-il-12 antibodies, epitopes, compositions, methods and uses. |
| US20070238094A1 (en) | 2005-12-09 | 2007-10-11 | Baylor Research Institute | Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis |
| WO2009114040A2 (en) | 2007-09-28 | 2009-09-17 | Centocor Ortho Biotech Inc. | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses |
| WO2012074396A1 (en) * | 2010-11-30 | 2012-06-07 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg | Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle |
| EP2729174A1 (en) | 2011-07-08 | 2014-05-14 | Merck Sharp & Dohme Corp. | Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| US9809854B2 (en) * | 2012-11-15 | 2017-11-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
| US20170002060A1 (en) | 2014-01-08 | 2017-01-05 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
| WO2015175424A1 (en) * | 2014-05-12 | 2015-11-19 | Biogen Ma Inc. | Biomarkers predictive of lupus progression and uses thereof |
| US11643460B2 (en) | 2014-10-28 | 2023-05-09 | Staley Brod | Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease |
| CN108290058B (zh) | 2015-09-17 | 2023-05-16 | 美国安进公司 | 使用il23途径生物标志物预测il23拮抗剂的临床应答 |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| CN109071653A (zh) * | 2016-03-29 | 2018-12-21 | 詹森生物科技公司 | 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣 |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法 |
-
2019
- 2019-05-17 EP EP19804426.5A patent/EP3793521A4/en not_active Withdrawn
- 2019-05-17 WO PCT/IB2019/054104 patent/WO2019220412A2/en not_active Ceased
- 2019-05-17 US US16/415,231 patent/US11578124B2/en active Active
- 2019-05-17 JP JP2020564482A patent/JP7421500B2/ja active Active
-
2023
- 2023-01-13 US US18/154,116 patent/US20230279097A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525236A5 (enExample) | ||
| US11045546B1 (en) | Methods of treating coronavirus infection | |
| AU2008247398B2 (en) | Interferon alpha-induced pharmacodynamic markers | |
| JP2018008951A (ja) | インターフェロンγに対する抗体を使用した治療方法 | |
| Lopes et al. | Temporal profiling of cytokine-induced genes in pancreatic β-cells by meta-analysis and network inference | |
| US20150044222A1 (en) | Interferon alpha-induced pharmacodynamic markers and uses thereof | |
| JP2014519487A5 (enExample) | ||
| JP2015524793A (ja) | 炎症阻害用の抗ｃｘｃｌ９、抗ｃｘｃｌ１０、抗ｃｘｃｌ１１、抗ｃｘｃｌ１３、抗ｃｘｃｒ３、及び抗ｃｘｃｒ５作用剤 | |
| JP2021525236A (ja) | 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 | |
| Park et al. | Interleukin 13–and interleukin 17A–induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution | |
| CN103732251A (zh) | 用针对干扰素-α的抗体治疗全身性红斑狼疮、硬皮病以及肌炎的方法 | |
| CN113692287A (zh) | I型干扰素标记及使用方法 | |
| JP2019519475A (ja) | ヒト化抗ｃｌｅｖｅｒ−１抗体およびその使用 | |
| US20230374124A1 (en) | Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof | |
| TW202239767A (zh) | 用於治療類風濕性關節炎之組成物及方法 | |
| JP2023505203A5 (enExample) | ||
| CN114025796A (zh) | 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法 | |
| US20100261172A1 (en) | Interferon alpha-induced pharmacodynamic markers | |
| CA3214379A1 (en) | Treatments for prurigo nodularis | |
| JP2008515819A (ja) | 乾癬の予防及び治療用ｉ型インターフェロンブロッキング剤 | |
| JP2025134820A (ja) | Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法 | |
| WO2019183437A1 (en) | Methods and compositions for antibody to high affinity receptor for ige | |
| US20260078170A1 (en) | Pan-Neutralizing SARS-CoV-2 mAb Composition and Methods of Treatment Thereof | |
| US12173039B1 (en) | TPL2 inhibiting agents, uses thereof, and detection of TPL2 | |
| US20260036592A1 (en) | DETECTION OF ANTI-VIRAL CDR3s IN CANCER |